Barbara Kiesewetter

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 32

Top Venues

Therapeutic advances in medical oncology

Hematological oncology

ESMO open

Cancers

Medical University Vienna

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Medical University Vienna Oct 01 2010

Austria

Resident :: Medicine I, Clinical Division of Oncology

Publications

Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Elisabeth Kretschmer-Chott, Markus Raderer, Barbara Kiesewetter
From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms. Therapeutic advances in medical oncology 16 (2024)
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Petar Popov, Elisabeth Kretschmer-Chott, Alexander Haug, Marius E Mayerhoefer, Markus Raderer, Barbara Kiesewetter
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms. Endocrine-related cancer 31 (3) (2024)
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Elisabeth Kretschmer-Chott, Markus Raderer, Barbara Kiesewetter
From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms. Therapeutic advances in medical oncology 16 (2024)
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Petar Popov, Elisabeth Kretschmer-Chott, Alexander Haug, Marius E Mayerhoefer, Markus Raderer, Barbara Kiesewetter
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms. Endocrine-related cancer 31 (3) (2024)
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Petar Popov, Elisabeth Kretschmer-Chott, Alexander Haug, Marius E Mayerhoefer, Markus Raderer, Barbara Kiesewetter
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms. Endocrine-related cancer 31 (3) (2024)
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Elisabeth Kretschmer-Chott, Markus Raderer, Barbara Kiesewetter
From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms. Therapeutic advances in medical oncology 16 (2024)
Petar Popov, Ariane Steindl, Ladislaia Wolff, Elisabeth S Bergen, Franziska Eckert, Josa Maria Frischer, Georg Widhalm, Thorsten Fuereder, Markus Raderer, Anna Sophie Berghoff, Matthias Preusser, Barbara Kiesewetter
Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases - data from a tertiary care center. Clinical & experimental metastasis (2023)
Markus Raderer, Barbara Kiesewetter, Ming-Qing Du
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal. Therapeutic advances in medical oncology 15 (2023)
Markus Raderer, Barbara Kiesewetter, Ming-Qing Du
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal. Therapeutic advances in medical oncology 15 (2023)
Markus Raderer, Barbara Kiesewetter, Ming-Qing Du
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal. Therapeutic advances in medical oncology 15 (2023)
Barbara Kiesewetter, Philipp Melhorn, Simon Macheiner, Ladislaia Wolff, Elisabeth Kretschmer-Chott, Alexander Haug, Peter Mazal, Markus Raderer
Does the dose matter? Antiproliferative efficacy and toxicity of everolimus in patients with neuroendocrine tumors - Experiences from a tertiary referral center. Journal of neuroendocrinology (2023)
Philipp Melhorn, Elisabeth Kretschmer-Chott, Ladislaia Wolff, Alexander Haug, Peter Mazal, Markus Raderer, Barbara Kiesewetter
Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna. Therapeutic advances in medical oncology 14 (2022)
Barbara Kiesewetter, Markus Raderer
How I treat neuroendocrine tumours. ESMO open 5 (4) (2021)
Markus Raderer, Barbara Kiesewetter
What you always wanted to know about gastric MALT-lymphoma: a focus on recent developments. Therapeutic advances in medical oncology 13 (2021)
Marius Mayerhoefer, Markus Raderer, Wolfgang Lamm, Michael Weber, Barbara Kiesewetter, Johannes Rohrbeck, Ingrid Simonitsch-Klupp, Marcus Hacker, Asha Leisser, Lukas Nics, Stefan Schmitl, Hans-Juergen Wester, Alexander R Haug
CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line H. pylori eradication. Blood (2021)
Barbara Kiesewetter, Philipp Riss, Christian Scheuba, Peter Mazal, Elisabeth Kretschmer-Chott, Alexander Haug, Markus Raderer
Management of adrenocortical carcinoma: are we making progress? Therapeutic advances in medical oncology 13 (2021)
Barbara Kiesewetter, Christiane Copie-Bergman, Michael Levy, Fangtian Wu, Jehan Dupuis, Caroline Barau, Luca Arcaini, Marco Paulli, Marco Lucioni, Arturo Bonometti, Antonio Salar-Silvestre, Maria Concepción Fernández-Rodríguez, Miguel Angel Piris, Francesco Cucco, Rachel Dobson, Yan Li, Zi Chen, Cyrielle Robe, Ingrid Simonitsch-Klupp, Andrew Wotherspoon, Markus Raderer, Ming Qing Du
Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers 13 (12) (2021)
Christoph Kornauth, Tea Pemovska, Gregory I Vladimer, Günther Bayer, Michael M Bergmann, Sandra Eder, Ruth Eichner, Martin Erl, Harald Esterbauer, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, Alexander Gaiger, Klaus Geissler, Hildegard T Greinix, Wolfgang Gstöttner, Marcus Hacker, Bernd Lorenz Hartmann, Alexander W Hauswirth, Tim Heinemann, Daniel Heintel, Mir Alireza Hoda, Georg Hopfinger, Ulrich Jaeger, Lukas Kazianka, Lukas Kenner, Barbara Kiesewetter, Nikolaus Krall, Gerhard Krajnik, Stefan Kubicek, Trang Le, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, Katsuhiro Miura, Leonhard Müllauer, Peter Neumeister, Thomas Noesslinger, Katharina Ocko, Leopold Öhler, Michael Panny, Alexander Pichler, Edit Porpaczy, Gerald W Prager, Markus Raderer, Robin Ristl, Reinhard Ruckser, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, Ilse Schwarzinger, Edgar Selzer, Christian Sillaber, Cathrin Skrabs, Wolfgang R Sperr, Ismet Srndic, Renate Thalhammer, Peter Valent, Emiel van der Kouwe, Katrina Vanura, Stefan Vogt, Cora Waldstein, Dominik Wolf, Christoph C Zielinski, Niklas Zojer, Ingrid Simonitsch-Klupp, Giulio Superti-Furga, Berend Snijder, Philipp B Staber
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders. Cancer discovery (2021)
Markus Raderer, Barbara Kiesewetter
How I treat MALT lymphoma: 'a subjective interpretation of the gospel according to Isaacson….' ESMO open 5 (4) (2021)
Barbara Kiesewetter, Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, María-Victoria Mateos, Gert J Ossenkoppele, Kimmo Porkka, Markus Raderer, Josep-Maria Ribera, Lydia Scarfò, Ruth Wester, Panagiota Zygoura, Pieter Sonneveld
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO open 5 (1) (2021)
Antonia Pokorny, Barbara Kiesewetter, Markus Raderer
Experience with clarithromycin as antineoplastic therapy for extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma) outside of clinical trials: Real-world data from the University of Vienna. Hematological oncology 38 (3) (2020)
Barbara Kiesewetter, Ingrid Simonitsch-Klupp, Marius E Mayerhoefer, Werner Dolak, Julius Lukas, Markus Raderer
First Line Systemic Treatment for MALT Lymphoma-Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna. Cancers 12 (12) (2020)
Barbara Kiesewetter, Markus Raderer
Immunomodulatory treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma). Hematological oncology 38 (4) (2020)
Barbara Kiesewetter, Ingrid Simonitsch-Klupp, Werner Dolak, Marius E Mayerhoefer, Markus Raderer
Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Cancers 12 (2) (2020)
Barbara Kiesewetter, Wolfgang Lamm, Ortrun Neuper, Marius E Mayerhoefer, Ingrid Simonitsch-Klupp, Markus Raderer
Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna. Hematological oncology 37 (4) (2019)
Georg Richtig, Erika Richtig, Alexandra Böhm, Christoph Oing, Farastuk Bozorgmehr, Stephan Kruger, Barbara Kiesewetter, Christoph Zielinski, Anna Sophie Berghoff
Awareness of predatory journals and open access among medical oncologists: results of an online survey. ESMO open 4 (6) (2019)
Barbara Kiesewetter, Wolfgang Lamm, Werner Dolak, Julius Lukas, Marius E Mayerhoefer, Michael Weber, Ana-Iris Schiefer, Christoph Kornauth, Günther Bayer, Ingrid Simonitsch-Klupp, Markus Raderer
Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. British journal of haematology 186 (3) (2019)
Heimo Lagler, Barbara Kiesewetter, Werner Dolak, Markus Obermueller, Ingrid Simonitsch-Klupp, Julius Lukas, Ortrun Neuper, Wolfgang W Lamm, Marius E Mayerhoefer, Markus Raderer
Treatment of mucosa associated lymphoid tissue lymphoma with a long-term once-weekly regimen of oral azithromycin: Results from the phase II MALT-A trial. Hematological oncology 37 (1) (2018)
Barbara Kiesewetter, Ortrun Neuper, Marius E Mayerhoefer, Werner Dolak, Julius Lukas, Ingrid Simonitsch-Klupp, Markus Raderer
A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. Hematological oncology 36 (1) (2017)
Andrés José Maria Ferreri, Caterina Cecchetti, Barbara Kiesewetter, Marianna Sassone, Teresa Calimeri, Salvatore Perrone, Maurilio Ponzoni, Markus Raderer
Clarithromycin as a "repurposing drug" against MALT lymphoma. British journal of haematology 182 (6) (2017)
Barbara Kiesewetter, Ingrid Simonitsch-Klupp, Christoph Kornauth, Werner Dolak, Julius Lukas, Marius E Mayerhoefer, Markus Raderer
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Hematological oncology 36 (1) (2017)
Barbara Kiesewetter, Markus Raderer, Gerald W Prager, Thorsten Fuereder, Christine Marosi, Matthias Preusser, Michael Krainer, Gottfried J Locker, Thomas Brodowicz, Christoph C Zielinski
The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO open 2 (3) (2017)

Barbara Kiesewetter.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Barbara Kiesewetter